# Biolargo, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Biolargo, Inc.).

## Overview

BioLargo, Inc. is a U.S.-based developer and commercializer of environmental technologies, with operations spanning odor control, water treatment, and engineering services. The company sells CupriDyne Clean and related odor/VOC solutions through ONM Environmental, while its BEST subsidiary markets water-treatment technologies such as AEC for PFAS removal, AOS for micro-pollutants, and AROS for industrial water reuse. It also operates BLEST, an engineering business that provides air-quality compliance services and supports internal technology development. BioLargo’s business model combines product sales, service contracts, and technology commercialization, but it remains capital constrained and dependent on external financing to fund growth.

## Products & services

• CupriDyne® Clean industrial odor-control product
• Odor/VOC control systems, installation and maintenance
• AEC PFAS water treatment technology
• AOS micro-pollutant removal technology
• AROS industrial water reuse technology
• Air quality control compliance services for U.S. Air Force bases
• Private-label odor-control products, including Pooph

- **Industrial odor and VOC solutions** (45%) — Odor-control chemicals, delivery systems, and related field services for landfills, wastewater, and municipal sanitation sites.
- **Private-label consumer odor products** (30%) — Third-party branded pet-odor and related odor-control products sold through private-label arrangements.
- **Water treatment technologies** (15%) — Proprietary technologies and equipment platforms for PFAS removal, micropollutant treatment, and water reuse.
- **Engineering and compliance services** (10%) — Air-quality control engineering, installation, maintenance, and compliance services delivered by BLEST.

- CupriDyne® Clean industrial odor-control product
- Odor/VOC control systems, installation and maintenance
- AEC PFAS water treatment technology
- AOS micro-pollutant removal technology
- AROS industrial water reuse technology
- Air quality control compliance services for U.S. Air Force bases
- Private-label odor-control products, including Pooph

## Customers

BioLargo sells to a mix of municipal, industrial, government, and consumer-channel customers. ONM Environmental serves cities, counties, landfills, transfer stations, wastewater treatment facilities, and other industrial sites that need odor and VOC mitigation systems. BLEST’s third-party customers include U.S. Air Force bases and other clients needing air-quality compliance and engineering support, while its internal work supports BioLargo’s own PFAS and battery development programs. The company also sells private-label odor products to third parties, with Pooph representing the most important consumer-oriented revenue stream in recent periods.

- **Municipal waste and sanitation operators** (primary) — Cities, counties, landfills, and transfer stations buy odor-control products and installed systems to reduce nuisance odors and maintain compliance.
- **Private-label consumer brand partners** (primary) — Third-party brands buy odor-control formulations and packaging support, with Pooph historically driving a large share of consolidated revenue.
- **Government and defense facilities** (secondary) — U.S. Air Force bases buy ongoing air-quality control compliance services and related engineering work.
- **Industrial water-treatment customers** (secondary) — Industrial users and project partners evaluate AEC, AOS, and AROS technologies for PFAS removal, micropollutant treatment, and reuse applications.
- **Internal development programs** (secondary) — BioLargo subsidiaries use BLEST engineering resources to advance proprietary technologies, especially PFAS and battery-related projects.

- Cities and counties buying odor-control systems for municipal waste sites
- Landfills and transfer stations needing odor/VOC mitigation
- Wastewater treatment facilities seeking odor-control products and services
- U.S. Air Force bases purchasing air-quality compliance services
- Private-label consumer brands buying odor-control formulations
- Internal BioLargo projects using BLEST engineering support

## Geography

BioLargo is headquartered in the United States and its reported commercial activity is primarily domestic. The company specifically cites ongoing contracts with cities and counties in Southern California, which makes that region important for odor-control revenue and field deployment. BLEST also performs work at U.S. Air Force bases across the country, giving the engineering business a broader U.S. footprint tied to government compliance needs. The company’s technology commercialization efforts are U.S.-centric, and its operational exposure is therefore concentrated in domestic municipal, industrial, and defense markets.

- United States is the core operating and revenue market
- Southern California is a key region for municipal odor-control contracts
- U.S. Air Force bases provide recurring nationwide engineering revenue
- Domestic focus reduces foreign-currency complexity but concentrates U.S. demand risk
- Technology commercialization and customer development are centered in the U.S.

## Strategy

BioLargo is trying to convert its technology portfolio into repeatable commercial revenue through a mix of product sales, service contracts, and third-party distribution. A major strategic theme is to win early PFAS and water-treatment deployments, then use those reference projects to secure larger follow-on contracts and broader market adoption. The company is also trying to expand beyond its own sales infrastructure by using partners and private-label channels, as shown by the Pooph relationship and other distribution efforts. At the same time, management is focused on conserving capital, using contract manufacturers and stock-based compensation where possible, because the business remains dependent on external financing.

- **Commercialize PFAS and water-treatment technologies** (medium-term) — Reference projects and early deployments are intended to validate the technology and unlock larger customer wins.
- **Expand recurring odor-control contracts** (short-term) — Recurring municipal and industrial service contracts provide more stable revenue than one-off product sales.
- **Broaden third-party distribution and private-label sales** (short-term) — Partner-led channels can scale revenue without requiring BioLargo to build a large internal sales force.
- **Conserve capital while scaling operations** (short-term) — The company has limited liquidity and needs to fund growth without overextending its balance sheet.

- Use early PFAS and water-treatment deployments as proof points for larger contracts
- Expand odor-control and water-treatment reach through third-party partners
- Grow recurring service revenue from municipal and government contracts
- Leverage private-label channels to reduce reliance on in-house distribution
- Use contract manufacturers and outsourced capacity to scale without heavy capex
- Preserve cash while funding technology commercialization and field trials

## Risks

BioLargo faces substantial going-concern and liquidity risk because operating cash flow has been negative and management says current gross profits are not sufficient to fund operations. Revenue concentration is another major issue: the Pooph private-label relationship has historically represented a large share of consolidated revenue, so any decline in that channel can materially affect results. The company also depends on a small number of recurring municipal and government contracts, which can be delayed, renewed slowly, or lost to competitors. More broadly, commercialization risk is high in PFAS and water-treatment markets because customers may require long sales cycles, field validation, and regulatory confidence before adopting new technologies.

- **Going-concern and funding risk** [critical] — Management states that gross profits are not sufficient to fund current operations and that additional capital will be needed.
- **Customer and product concentration** [high] — Pooph has represented a large portion of consolidated revenue, so a decline in that relationship can sharply reduce sales and operating income.
- **Commercial adoption risk for PFAS technologies** [high] — New water-treatment technologies require validation, reference projects, and customer confidence before scaling.
- **Credit losses and collection risk** [high] — The company disclosed credit loss expense tied to customer contractual defaults and note receivable issues.
- **Execution and staffing constraints** [medium] — Management notes the need for more qualified staff and reliance on contract manufacturers as demand grows.

- Going-concern and liquidity pressure due to recurring operating cash burn
- Heavy dependence on external financing to fund operations and technology development
- Revenue concentration in the Pooph private-label channel
- Customer concentration in municipal and government contracts
- Commercialization risk for PFAS and water-treatment technologies
- Credit loss and collection risk on receivables and note receivables
- Execution risk from scaling engineering and manufacturing capacity

## Accounting

BioLargo’s reported results are highly sensitive to revenue recognition judgments because the business mixes product sales, service contracts, and internal intersegment work. BLEST’s engineering revenue can fluctuate with the timing of contract milestones and product sales recognition, which makes quarterly comparisons volatile. The company also has significant estimates around credit losses, including receivables and note receivables, and those estimates can materially affect operating loss in periods when customers default or collections weaken. In addition, management highlights valuation judgments for debt with equity or derivative features, warrant components, beneficial conversion features, and share-based payments, all of which can materially change reported expenses and equity values.

- **Revenue recognition timing** — Can create large quarter-to-quarter swings in revenue and margin
- **Credit loss allowances** — Can materially increase operating losses in affected periods
- **Derivative and warrant valuation** — Can create non-cash expense and volatility in earnings and equity
- **Share-based compensation** — Reduces cash outflow but increases non-cash compensation expense and dilution
- **Intersegment revenue elimination** — Affects segment reporting and can obscure underlying external demand

- Revenue recognition across product sales, services, and contract milestones
- Quarterly volatility from timing of BLEST service and product revenue
- Credit loss allowances for receivables and note receivables
- Valuation of warrants, beneficial conversion features, and derivative instruments
- Share-based compensation used in lieu of cash payments
- Intersegment revenue elimination for internal engineering work

---

*Last updated: 2026-08-11T04:46:22.652970+00:00*